RC48- ADC
RC48-TA001
Phase 2 small_molecule active
Quick answer
RC48- ADC for Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active